March 2016

New Product - Gamunex

Gamunex (human normal immunoglobulin) is indicated as replacement therapy in primary immunodeficiency diseases, symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment, immunomodulation in ITP, in patients at high risk of bleeding or prior to surgery to correct the platelet count, Guillain-Barr√© syndrome, chronic Inflammatory demyelinating polyneuropathy and in Kawasaki disease. Gamunex is contraindicated in individuals with known anaphylactic or severe systemic response to human immunoglobulin, especially severe, selective IgA deficiencies. Gamunex is available as 10% solution for infusion in 1 g/10 mL, 2.5 g/25 mL, 5 g/50 mL, 10 g/100 mL and 20 g/200 mL vials.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia¬†Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629